US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Filana Therapeutics

0.8860

-0.0387-4.19%

Pre-market: 0.94010.0541+6.11%04:17 EDT

Volume:776.91K

Turnover:713.33K

Market Cap:42.80M

PE:-1.01

High:0.9467

Open:0.9299

Low:0.8641

Close:0.9247

52wk High:4.98

52wk Low:0.6701

Shares:48.31M

Float Shares:47.32M

Volume Ratio:0.33

T/O Rate:1.64%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8752

EPS(LYR):-1.8836

ROE:-55.78%

ROA:-7.14%

PB:0.67

PE(LYR):-0.47

Loading ...

Overview Company News Filings

Filana Therapeutics CEO Richard Barry Acquires USD 78,196 of Common Shares

Pepsi Stock Sits Near 52-Week Low as JPMorgan Downgrades Ratings, What's Driving the Move?

U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify

NASDAQ Trade Halt Volatility Trading Pause at 10:42 Am

Filana can proceed with study as hold lifted, says Lucid Capital

Filana Therapeutics Shares Jump 35% to $1 Premarket After FDA Lifts Clinical Hold on Co's Epilepsy Drug

THOMSON REUTERS

Filana Therapeutics announces U.S. FDA lifted clinical hold on simufilam

Filana Therapeutics Plans Phase 2a Simufilam Trial in TSC-Related Epilepsy After FDA Lifts Clinical Hold

Filana Therapeutics, - Subjects Eligible for 48-Week Extension Study After Double-Blind Phase

THOMSON REUTERS

Filana Therapeutics, - Patient Screening for Phase 2a Study Expected to Begin by Q1 2027

THOMSON REUTERS

Filana Therapeutics, - FDA Lifts Clinical Hold on Filana's Simufilam for Tsc-Related Epilepsy

THOMSON REUTERS

Filana Therapeutics, - Phase 2a Study to Enroll 40 Subjects at 13 U.S. Sites over 16 Weeks

THOMSON REUTERS

NASDAQ Trade Halt Halt News Pending at 07:55 Am

Filana Therapeutics Receives NASDAQ Notice for Sub-$1 Minimum Bid Price Noncompliance

OncoZenge to Present BupiZenge Phase III Program at Pain Therapeutics Summit

Ensysce Biosciences to Present at Cantor Global Healthcare Conference

Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate

Benzinga Earnings

Filana Therapeutics Q2 FY26 Net Loss Narrows 80.55% to $8.6 Million

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

THOMSON REUTERS

Filana Therapeutics shareholders approved 2018 incentive plan amendment at annual meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/FLNA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FLNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FLNA\",,,,,undefined,":{"symbol":"FLNA","market":"US","secType":"STK","nameCN":"Filana Therapeutics","latestPrice":0.886,"timestamp":1790798400000,"preClose":0.9247,"halted":0,"volume":776905,"hourTrading":{"tag":"盘前","latestPrice":0.9401,"preClose":0.886,"latestTime":"04:17 EDT","volume":96,"amount":91.04390688,"timestamp":1790842666934,"change":0.0541,"changeRate":0.061061,"amplitude":0.010497},"delay":0,"changeRate":-0.041851411268519476,"floatShares":47317539,"shares":48307896,"eps":-0.875208,"marketStatus":"Pre-Mkt","change":-0.0387,"latestTime":"10-01 04:31:41 EDT","open":0.9299,"high":0.9467,"low":0.8641,"amount":713333.1634888,"amplitude":0.089326,"askPrice":0.97,"askSize":1,"bidPrice":0.8597,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.875208,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.886,"preHourTrading":{"tag":"盘前","latestPrice":0.9401,"preClose":0.886,"latestTime":"04:17 EDT","volume":96,"amount":91.04390688,"timestamp":1790842666934,"change":0.0541,"changeRate":0.061061,"amplitude":0.010497},"postHourTrading":{"tag":"盘后","latestPrice":0.9401,"preClose":0.886,"latestTime":"19:59 EDT","volume":105201,"amount":100422.13503,"timestamp":1790812784913,"change":0.0541,"changeRate":0.061061,"amplitude":0.117381},"volumeRatio":0.32861574605373184,"impliedVol":1.8742,"impliedVolPercentile":0.766},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FLNA\",,,,,undefined,":{"symbol":"FLNA","floatShares":47317539,"roa":"-7.14%","roe":"-55.78%","lyrEps":-1.883615,"volumeRatio":0.32861574605373184,"shares":48307896,"dividePrice":0,"high":0.9467,"amplitude":0.089326,"preClose":0.9247,"low":0.8641,"week52Low":0.6701,"pbRate":"0.67","week52High":4.98,"institutionHeld":0.3169,"latestPrice":0.886,"committee":0.980198,"eps":-0.875208,"divideRate":0,"volume":776905,"delay":0,"ttmEps":-0.875208,"open":0.9299,"prevYearClose":1.98,"prevWeekClose":0.7481,"prevMonthClose":0.886,"prevQuarterClose":0.886,"fiveDayClose":0.8701,"twentyDayClose":0.8573,"sixtyDayClose":1.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FLNA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-29","symbol":"FLNA","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785297600000,"reportTimeType":"pre","actualEps":-0.18},{"market":"US","date":"2026-05-07","symbol":"FLNA","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.21},{"market":"US","date":"2026-03-12","symbol":"FLNA","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FLNA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FLNA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1779854400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FLNA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FLNA","date":"2026-09-29","current":-1.012331,"percent":0.255474,"low":-1.176848,"twenty":-1.007864,"median":-0.877468,"eighty":-0.752824,"high":-0.548743,"avg":-0.87803,"sd":0.140207,"marketCap":41216296},"quantilePoints":[{"date":"2026-03-13","current":-1.035476,"twenty":-1.018822,"median":-0.993842,"eighty":-0.968861,"marketCap":94200397},{"date":"2026-03-20","current":-0.971755,"twenty":-1.052469,"median":-1.035476,"eighty":-0.980251,"marketCap":88403449},{"date":"2026-03-27","current":-0.939894,"twenty":-1.035476,"median":-0.99034,"eighty":-0.956117,"marketCap":85504975},{"date":"2026-04-02","current":-0.913343,"twenty":-1.035476,"median":-0.971755,"eighty":-0.913343,"marketCap":83089581},{"date":"2026-04-10","current":-0.913343,"twenty":-1.014236,"median":-0.950514,"eighty":-0.897413,"marketCap":83089581},{"date":"2026-04-17","current":-0.934584,"twenty":-0.998305,"median":-0.926619,"eighty":-0.886793,"marketCap":85021896},{"date":"2026-04-24","current":-0.881482,"twenty":-0.982375,"median":-0.918653,"eighty":-0.886793,"marketCap":80191107},{"date":"2026-05-01","current":-0.76997,"twenty":-0.971755,"median":-0.908033,"eighty":-0.860242,"marketCap":70046449},{"date":"2026-05-08","current":-0.722178,"twenty":-0.971755,"median":-0.897413,"eighty":-0.828381,"marketCap":65698738},{"date":"2026-05-15","current":-0.768948,"twenty":-0.952207,"median":-0.889448,"eighty":-0.793752,"marketCap":59901791},{"date":"2026-05-22","current":-0.799954,"twenty":-0.950514,"median":-0.881482,"eighty":-0.768948,"marketCap":62317185},{"date":"2026-05-29","current":-0.961185,"twenty":-0.950853,"median":-0.881482,"eighty":-0.769766,"marketCap":74877238},{"date":"2026-06-05","current":-0.868167,"twenty":-0.950853,"median":-0.884138,"eighty":-0.774113,"marketCap":67631054},{"date":"2026-06-12","current":-0.812356,"twenty":-0.942018,"median":-0.880569,"eighty":-0.790031,"marketCap":63283343},{"date":"2026-06-18","current":-0.750344,"twenty":-0.936708,"median":-0.870862,"eighty":-0.769561,"marketCap":58452554},{"date":"2026-06-26","current":-0.719338,"twenty":-0.931941,"median":-0.860242,"eighty":-0.763894,"marketCap":56037159},{"date":"2026-07-02","current":-0.775149,"twenty":-0.929817,"median":-0.854932,"eighty":-0.756545,"marketCap":60384870},{"date":"2026-07-10","current":-0.737942,"twenty":-0.927155,"median":-0.843362,"eighty":-0.756545,"marketCap":57486396},{"date":"2026-07-17","current":-0.669729,"twenty":-0.921847,"median":-0.823469,"eighty":-0.744143,"marketCap":52172527},{"date":"2026-07-24","current":-0.578075,"twenty":-0.918653,"median":-0.812356,"eighty":-0.737942,"marketCap":45032620},{"date":"2026-07-31","current":-1.096868,"twenty":-0.922912,"median":-0.812356,"eighty":-0.737942,"marketCap":46375580},{"date":"2026-08-07","current":-1.095725,"twenty":-0.938832,"median":-0.823469,"eighty":-0.737942,"marketCap":46327272},{"date":"2026-08-14","current":-1.080758,"twenty":-0.959945,"median":-0.843362,"eighty":-0.739037,"marketCap":45694438},{"date":"2026-08-21","current":-1.076873,"twenty":-0.988871,"median":-0.854932,"eighty":-0.743564,"marketCap":45530191},{"date":"2026-08-28","current":-1.054593,"twenty":-1.016358,"median":-0.860242,"eighty":-0.744143,"marketCap":44588188},{"date":"2026-09-04","current":-0.946391,"twenty":-1.024201,"median":-0.872615,"eighty":-0.744143,"marketCap":40013430},{"date":"2026-09-11","current":-0.924226,"twenty":-1.016888,"median":-0.881026,"eighty":-0.744143,"marketCap":39076257},{"date":"2026-09-18","current":-0.822651,"twenty":-1.014236,"median":-0.874368,"eighty":-0.750344,"marketCap":34781685},{"date":"2026-09-25","current":-0.882979,"twenty":-1.014236,"median":-0.877468,"eighty":-0.750344,"marketCap":37332342},{"date":"2026-09-29","current":-0.974841,"twenty":-1.007864,"median":-0.877468,"eighty":-0.752824,"marketCap":41216296}],"updateTime":1790811905354},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FLNA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672782891","title":"Filana Therapeutics CEO Richard Barry Acquires USD 78,196 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672782891","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672782891?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:04","pubTimestamp":1790798671,"startTime":"0","endTime":"0","summary":"Filana Therapeutics CEO Richard Barry acquires USD 78,196 of common sharesFilana Therapeutics President and CEO Richard Barry reported an open-market purchase of 93,091 common shares at $0.84.Holdings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL2tj49Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Filana Therapeutics CEO Richard Barry Acquires USD 78,196 of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121372937","title":"Pepsi Stock Sits Near 52-Week Low as JPMorgan Downgrades Ratings, What's Driving the Move?","url":"https://stock-news.laohu8.com/highlight/detail?id=1121372937","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121372937?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:30","pubTimestamp":1790677835,"startTime":"0","endTime":"0","summary":"Even though PepsiCo (PEP) shares are hovering near their 52-week low, analysts at JPMorgan clearly do not see this as an appealing buying opportunity.JPMorgan analyst Andrea Teixeira downgraded...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN8TJ469.HKD","LU0098860793.USD","LU1894683264.USD","LU1244550577.SGD","IE000F7OJYX1.SGD","IE00BLSP4452.SGD","IE00BBT3K403.USD","FTXG","LU0320765646.SGD","LU1162221912.USD","LU1244550221.USD","BK4581","BK4585","BK4007","LU1244550494.USD","BK4534","IE00B3T34201.USD","IE000WAW04H5.SGD","LU1929549753.HKD","BK4566","BK4533","LU1894683348.USD","BK4504","IE000SO60NU8.SGD","FLNA","IE0000B7K699.USD","IE000BZT7R73.USD","IE00BLSP4239.USD","BK4588","IE000MB6IJN5.SGD","BK4550","LU0234572021.USD","BK4177","PEP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669237741","title":"U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify","url":"https://stock-news.laohu8.com/highlight/detail?id=2669237741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669237741?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:41","pubTimestamp":1790091697,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, ShopifySeptember 22 (Reuters)-The tech-heavy Nasdaq hit an intraday record high for the first time since early June on Tuesday, underpinned by s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL6N45E0HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KMI","ODDS","MSFT","BFLY","CONY","HUBC","SLXN","GRML","OKE","EPD","GOOGL","VRTX","MRNA","RIOT","SF","ET","AZO","GEMI","DAVA","VLO","MLKN","SHOP","THO","DCOY","VICR","CLDX","HUT","AMP","RSI","FLNA","SHPU","DNA","BTTC","SOS","AMGN","CXT","EAF","GME","RJF","VKTX","USNG","LEN","COIN","MPWR","CW","ONON","SCHW","MARA","ZEO","CMPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669116128","title":"NASDAQ Trade Halt Volatility Trading Pause at 10:42 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2669116128","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669116128?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:42","pubTimestamp":1790088156,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 10:42 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nAQN2MKBGF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669140714","title":"Filana can proceed with study as hold lifted, says Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2669140714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669140714?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:05","pubTimestamp":1790085948,"startTime":"0","endTime":"0","summary":"Lucid Capital analyst Elemer Piros reiterates a Buy rating on Filana Therapeutics (FLNA) with an $8 price target after the company said the FDA has...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/filana-can-proceed-with-study-as-hold-lifted-says-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/filana-can-proceed-with-study-as-hold-lifted-says-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4596","BK4588","BK4551","LCID","BK4585","BK4007","BK4099","FLNA","LABU","LCIZ","BK4555","LCDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142563","title":"Filana Therapeutics Shares Jump 35% to $1 Premarket After FDA Lifts Clinical Hold on Co's Epilepsy Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142563?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:53","pubTimestamp":1790081612,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0U4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442921","title":"Filana Therapeutics announces U.S. FDA lifted clinical hold on simufilam","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442921","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442921?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:20","pubTimestamp":1790079649,"startTime":"0","endTime":"0","summary":"Filana Therapeutics (FLNA) announced that the U.S. Food and Drug Administration, FDA, has lifted the clinical hold on the Company’s investigational...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-announces-u-s-fda-lifted-clinical-hold-on-simufilam-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-announces-u-s-fda-lifted-clinical-hold-on-simufilam-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","FLNA","SYNB","BK4585","IBB","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114141","title":"Filana Therapeutics Plans Phase 2a Simufilam Trial in TSC-Related Epilepsy After FDA Lifts Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114141","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669114141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:04","pubTimestamp":1790078686,"startTime":"0","endTime":"0","summary":"Filana Therapeutics plans Phase 2a simufilam trial in TSC-related epilepsy after FDA lifts clinical holdFilana Therapeutics cleared to restart simufilam development in TSC-related epilepsy after the F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL3CJrmM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419681","title":"Filana Therapeutics, - Subjects Eligible for 48-Week Extension Study After Double-Blind Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419681?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUAS7GVN:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419531","title":"Filana Therapeutics, - Patient Screening for Phase 2a Study Expected to Begin by Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419531?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUAS7GVN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141969","title":"Filana Therapeutics, - FDA Lifts Clinical Hold on Filana's Simufilam for Tsc-Related Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141969","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141969?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUAS7GVN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141933","title":"Filana Therapeutics, - Phase 2a Study to Enroll 40 Subjects at 13 U.S. Sites over 16 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141933?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUAS7GVN:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141530","title":"NASDAQ Trade Halt Halt News Pending at 07:55 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141530","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141530?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:55","pubTimestamp":1790078100,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 07:55 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nAQN2MK9IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668733199","title":"Filana Therapeutics Receives NASDAQ Notice for Sub-$1 Minimum Bid Price Noncompliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2668733199","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668733199?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:16","pubTimestamp":1789762596,"startTime":"0","endTime":"0","summary":"Filana Therapeutics receives Nasdaq notice for sub-$1 minimum bid price noncomplianceNasdaq flagged Filana Therapeutics for noncompliance with the $1 minimum bid-price rule after 30 straight business ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL5Yc4rl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665390926","title":"OncoZenge to Present BupiZenge Phase III Program at Pain Therapeutics Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2665390926","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665390926?lang=en_us&edition=fundamental","pubTime":"2026-09-07 16:17","pubTimestamp":1788769025,"startTime":"0","endTime":"0","summary":"OncoZenge to present BupiZenge Phase III program at Pain Therapeutics SummitOncoZenge will present its Phase III BupiZenge program at the Pain Therapeutics Summit on Sept. 28-29 in the San Francisco B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nNDL7W4GJW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664425811","title":"Ensysce Biosciences to Present at Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664425811","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664425811?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:32","pubTimestamp":1788352370,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences to present at Cantor Global Healthcare ConferenceEnsysce will present at the 2026 Cantor Global Healthcare Conference in New York on September 10 at 9:10 a.m. ET.Management plans t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDLbw8Nkj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC","FLNA","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655860857","title":"Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860857","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655860857?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:04","pubTimestamp":1785326668,"startTime":"0","endTime":"0","summary":"Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 18.18 percent. This is a 80.43 percent increase over losses of $(0.92) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60756874/filana-therapeutics-q2-eps-0-18-beats-0-23-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655867047","title":"Filana Therapeutics Q2 FY26 Net Loss Narrows 80.55% to $8.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655867047","media":"Reuters","labels":["policyRegulatory","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655867047?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:04","pubTimestamp":1785326647,"startTime":"0","endTime":"0","summary":"Filana Therapeutics Q2 FY26 net loss narrows 80.55% to $8.6 millionFilana Therapeutics posted a GAAP net loss of USD 8.6 million, or USD 0.18 per share, in Q2 2026, narrowing from USD 44.2 million.R&D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL6BRZbp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FLNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655672148","title":"Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655672148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655672148?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:00","pubTimestamp":1785326402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA5LS1PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FLNA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643717272","title":"Filana Therapeutics shareholders approved 2018 incentive plan amendment at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643717272","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643717272?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:24","pubTimestamp":1781519072,"startTime":"0","endTime":"0","summary":"Filana Therapeutics held its annual shareholder meeting on June 11, 2026.Shareholders adopted an amendment to the 2018 Omnibus Incentive Plan, lifting authorized shares to 9,000,000 and extending the plan through Jan. 31, 2030.The amendment also bars option or SAR repricing, replacement, or cash-outs without shareholder approval, while tightening annual equity award limits.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL5Rh2sX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FLNA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}